BioLineRx (BLRX) Phase II/III CLARITY Missed Primary Endpoint; Will Terminate Study
Tweet Send to a Friend
BioLineRx (NASDAQ: BLRX) announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
